Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,85
KB10172,42
PKN69,8869,920,89
Msft432,63432,85-0,16
Nokia4,3014,459-0,20
IBM250,94251,20,79
Mercedes-Benz Group AG53,7353,74-0,24
PFE22,7822,79-0,46
07.05.2025 20:11:56
Indexy online
AD Index online
select
AD Index online
 

  • 06.05.2025
China Pharm (1093.HK, Hong Kong)
Závěr k 6.5.2025 Změna (%) Změna (HKD) Objem obchodů (HKD)
5,84 -5,96 -0,37 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiCSPC Pharmaceutical Group Ltd
Ticker1093
Kmenové akcie:Ordinary Shares
RIC1093.HK
ISINHK1093012172
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2024 21 400
Akcie v oběhu k 24.01.202511 543 701 732
MěnaCNY
Kontaktní informace
UliceNo.896 Zhongshandong Street
MěstoSHIJIAZHUANG
PSČ050035
ZeměChina
Kontatní osoba 
Funkce kontaktní osoby 
Telefon8631 187 037 015
Fax8631187039608

Business Summary: CSPC Pharmaceutical Group Ltd is an investment holding company primarily engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through three segments. The Finished Drugs segment in engaged in the research and development, manufacture and sale of pharmaceutical products and licensing business. The Bulk Products segment is engaged in the manufacture and sale of vitamin C, and antibiotic products in bulk powder form. The Functional Food and Others segment is engaged in the manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. The Company’s product therapeutic areas include nervous system, oncology, anti-infectives, cardiovascular, respiratory system, digestion and metabolism and others. The Company conducts its business in the domestic and overseas markets.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, CSPC Pharmaceutical Group Ltd revenues decreased 8% to RMB29.01B. Net income decreased 26% to RMB4.33B. Revenues reflect Finished Drugs segment decrease of 7% to RMB23.74B, Functional Food and Others segment decrease of 25% to RMB1.86B, Antibiotics segment decrease of 12% to RMB1.77B, The People's Republic of China segment decrease of 8% to RMB25.11B.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSAll Other Miscellaneous Food Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSOffices of Other Holding Companies
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Offices of Other Holding Companies
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Offices of Other Holding Companies
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICMedicinals And Botanicals
SICFood Preparations, Nec
SICCommercial Physical Research
SICHolding Companies, Nec



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardDongchen Cai7027.05.202201.01.1998
Executive Vice Chairman of the Board, Chief Executive OfficerCuilong Zhang5527.05.202209.07.2018
Executive DirectorXin Cai3328.05.202428.05.2024
Executive DirectorWeiping Chen4506.12.202406.12.2024
Executive DirectorChunlei Li4712.12.201712.12.2017
Executive DirectorWeidong Pan5521.05.201901.10.2006
Executive DirectorHuaiyu Wang6108.10.201008.10.2010
Executive DirectorZhenguo Wang5421.05.201920.01.2012
Executive DirectorBing Yao4728.05.202428.05.2024
Company SecretaryTain On Lo6901.01.202101.01.2021